Clinical Trials Logo
  1. Home
  2. Thrombotic Microangiopathies
  3. NCT05702996

Multicenter, Uncontrolled Pilot Study Evaluating the Efficacy of Eculizumab in the Treatment of Gemcitabine-induced Thrombotic Microangiopathies — GEMECULI  

Thrombotic Microangiopathies Clinical Trial

Official title:
Multicenter, Uncontrolled Pilot Study Evaluating the Efficacy of Eculizumab in the Treatment of Gemcitabine-induced Thrombotic Microangiopathies

Clinical Trial Summary

The main objective of this prospective multisite trial is to study the evolution of TMA (thrombotic microangiopathy) induced by gemcitabin and treated by eculizumab.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05702996
Study type Interventional
Source University Hospital, Rouen
Contact Steven GRANGE, MD
Phone +3323288
Email steven.grange@chu-rouen.fr
Status Not yet recruiting
Phase Phase 3
Start date March 2023
Completion date September 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04098445 - TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
Recruiting NCT03605511 - TTP and aHUS in Complicated Pregnancies
Not yet recruiting NCT05996679 - Automated Surveillance, Alert, and Rapid Diagnosis of Thrombotic Microangiopathies: the ASARD-TMA Study
Completed NCT02222545 - Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies Phase 2
Recruiting NCT06102694 - Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy
Completed NCT03252925 - A Safety and Efficacy Study of NAC in Patients With TA-TMA Phase 3
Recruiting NCT05855083 - Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA Phase 2
Completed NCT03384693 - Defibrotide TMA Prophylaxis Pilot Trial Phase 2
Not yet recruiting NCT02373267 - Screening of TMA Patients für ADAMTS13 Activity (Adamscreen) N/A
Recruiting NCT06098378 - Study of Patients With Thrombotic Microangiopathy Associated With Mitomycin C, Treated or Not With Eculizumab
Completed NCT02134171 - Early Predictive Factors of Cardiac and Cerebral Involvement in TMA N/A
Not yet recruiting NCT06182410 - Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma Phase 2
Withdrawn NCT04970004 - Study in Adult and Pediatric Patients With HSCT-TMA
Recruiting NCT03205995 - Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome Phase 3
Recruiting NCT04784455 - Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy Phase 3
Active, not recruiting NCT04570397 - Ravulizumab and COVID-19 Phase 3
Recruiting NCT05634928 - Construction of a Database for TMA
Completed NCT03518203 - Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients Phase 2
Recruiting NCT04745195 - Complement Prospective Evaluation of Thrombotic Microangiopathy on Endothelium
Recruiting NCT06291415 - The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP) Phase 1